Sofinnova Venture Partners X, L.P. 3
3 · Inozyme Pharma, Inc. · Filed Jul 23, 2020
Insider Transaction Report
Form 3
Sofinnova Venture Partners X, L.P.
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
Footnotes (2)
- [F1]The Series A-2 Convertible Preferred Stock is convertible into Common Stock on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.